Helen Tayton-Martin
Overview
Helen Tayton-Martin received an average of $1M in total compensation, including $398K in salary, at Adaptimmune Therapeutics from 2016 to 2021.
2021Adaptimmune TherapeuticsChief Business Officer
2020Adaptimmune TherapeuticsChief Business Officer
2019Adaptimmune TherapeuticsChief Business Officer
2018Adaptimmune TherapeuticsChief Business Officer
2017Adaptimmune TherapeuticsChief Business Officer
2016Adaptimmune TherapeuticsChief Business Officer
Source: SEC filings on April 21, 2022, April 20, 2020, and March 15, 2019.
Related executives
We found six more executives who work or worked at Adaptimmune Therapeutics.
Adrian Rawcliffe
Adaptimmune Therapeutics
Chief Executive Officer
William Bertrand
Adaptimmune Therapeutics
Chief Operating Officer
Gavin Wood
Adaptimmune Therapeutics
Chief Financial Officer
John Lunger
Adaptimmune Therapeutics
Chief Operating Officer
James Noble
Adaptimmune Therapeutics
Chief Executive Officer
Rafael Amado
Adaptimmune Therapeutics